Kidney Disease News and Research

RSS

Roche's peg-EPO product Mircera infringes Amgen patents

Amgen (Nasdaq: AMGN) today announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court's decision that Roche's peg-EPO product, Mircera, infringes four Amgen patents ('868, '698, '933 and '422) relating to recombinant erythropoietin (EPO) and processes for making it.

16 Sep 2009

Acute kidney injury multiplies the risk of future kidney complications

Patients who sustain injury to their kidneys and require in-hospital dialysis are three times more likely to need long-term dialysis later in life compared to those without a history of this condition, says a new study from St. Michael's Hospital.

16 Sep 2009

DaVita achieves target fistula usage rate in Virginia

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), has been recognized in the state of Virginia for reaching the End Stage Renal Disease (ESRD) Network's patient quality improvement goal.

16 Sep 2009

Long-term implications of severe acute kidney problems

Hospitalized patients who experience acute kidney problems that require dialysis are at increased risk of receiving chronic dialysis once discharged, but do not have an increased risk of death, according to a study in the September 16 issue of JAMA.

16 Sep 2009

NMQF launches the P.A.D. Atlas database that maps peripheral arterial disease prevalence by zip code

The National Minority Quality Forum (NMQF), one of the nation's leading voices in the health disparities discussion, is launching the P.A.D. Atlas, a database that maps by zip code peripheral arterial disease (P.A.D.) prevalence down to the street level, with the P.A.D. Coalition and support from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

15 Sep 2009

Phase III clinical trial results of DAR-31 published

Gilead Sciences, Inc. today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that includes a diuretic.

14 Sep 2009

DaVita Kidney Awareness Run/Walks increases CKD awareness

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), kicks off the DaVita Kidney Awareness Run/Walks(TM) - a 10-city series of 5K events raising funds and awareness of CKD across the nation -- on Sept. 13 at Stapleton Central Park in Denver.

14 Sep 2009

High-fat foods can induce binge eating

Findings from a new UT Southwestern Medical Center study suggest that fat from certain foods we eat makes its way to the brain. Once there, the fat molecules cause the brain to send messages to the body's cells, warning them to ignore the appetite-suppressing signals from leptin and insulin, hormones involved in weight regulation.

14 Sep 2009

Research data reveals why women discontinue treatment with current osteoporosis therapies

Amgen Inc. today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR).

14 Sep 2009

Scientists to get funding from The European Research Council

The European Research Council (ERC) expects to fund some 240 top researchers in its second prestigious ERC Starting Grant competition. This new wave of grantees follows the 299 researchers who received grants in the first Starting Grant competition in 2007.

11 Sep 2009

End stage renal disease can be delayed by early identification of CKD

Early identification of individuals with chronic kidney disease (CKD) can delay the onset of end stage renal disease (ESRD) and the need for chronic dialysis treatments. The incidence of CKD continues to grow, and early identification and intervention are critical to manage this costly disease.

11 Sep 2009

Wisconsin researchers identify the genetic region responsible for cardiovascular collapse during anesthesia

Researchers at The Medical College of Wisconsin in Milwaukee have identified the genetic region in rats responsible for cardiovascular collapse during anesthesia. While it is well known that people have different cardiovascular sensitivity to anesthesia causing some to collapse even when low doses are administered, the mechanism responsible for this susceptibility is not clear.

11 Sep 2009

ERC funds DiaDrug project to study the link between insulin resistance and albuminuria

11 Sep 2009

KidneyTel system helps manage health issues faced by kidney patients

Kidney patients often have a number of serious chronic health issues in addition to their kidney disease. Fresenius Medical Care, the world’s leading renal therapies company, has developed the KidneyTel system to provide an integrated care solution to assist patients, their families and their providers in managing the full range of health issues that kidney patients face on a daily basis.

11 Sep 2009

Endothelin research update to be presented at APS' 11th International Conference

Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases.

10 Sep 2009

FDA removes clinical hold on HEPLISAV hepatitis B vaccine

Dynavax Technologies Corporation today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the HEPLISAVTM Investigational New Drug (IND) application in individuals with chronic kidney disease.

10 Sep 2009

Affymax to complete Hematide Phase 3 clinical study by the end of 2009

Affymax, Inc. today announced that it has notified clinical trial sites to complete treatment of patients in the Phase 3 clinical program for the investigational drug, Hematide, by the end of 2009.

10 Sep 2009

Patient enrollment completed in Phase 2b clinical trial for Pyridorin

NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.

10 Sep 2009

DaVita offers individualized treatment options for students with kidney disease

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), supports dialysis patients' education by offering individualized treatment options based on optimal patient care standards and social circumstances.

10 Sep 2009

Regular usage of CGM devices help manage diabetes

The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors - six days per week or more - rather than the age of patients, and that benefits continue well past the time when people with type 1 diabetes begin using the devices - including experiencing fewer low blood sugar emergencies.

9 Sep 2009